Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ATA Launches Coalition To Advance Telehealth Patient Advocacy

Executive Summary

The American Telehealth Association has created a coalition with the mission of ensuring patients have a voice in the future of telehealth.

You may also be interested in...



Digital Health Roundup: Telehealth Strong, Diabetes Recalls And Expansions, AI And Radiology

In this month’s Digital Health Roundup, Medtech Insight’s Reed Miller offers a recap from the recent TCT 2022 meeting and talks about Butterfly Network’s expansion into Africa while Marion Webb highlights her interview with Aidoc’s CEO Elad Walach discussing plans for the AI-based software company.

Exec Chat: Telehealth Offers New Options For High-Acuity Cardiac Patients

Industry veteran Stuart Long spoke to Medtech Insight about the new world of care virtual telemetry is creating for cardiac patients. Long is the CEO of InfoBionic, a Massachusetts-based digital technology firm that specializes in remote cardiac monitoring. 

US Agencies Publish Guidance To Ensure Telehealth Access Equality

The US Departments of Health and Human Services and Justice have published guidance on protections in federal laws to help Americans with disabilities or limited English proficiency to access telehealth. The guidance coincides with the 32nd anniversary of the American with Disabilities Act.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145859

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel